Axonics, Inc. (NASDAQ: AXNX) has received regulatory approval from the Therapeutic Goods Administration to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia.
This cutting-edge device features a 20-year functional life and reduces recharge frequency to once every 6 to 10 months for only one hour. The implant utilizes the same small 5cc form factor as the previous generation (Axonics R15). Paired with intuitive remote control and enhanced MRI compatibility, the R20 builds on Axonics' commitment to improving incontinence care.
The Axonics R15 is designed to treat bladder and bowel dysfunctions, such as overactive bladder and fecal incontinence. By delivering electrical stimulation to the sacral nerves, this implantable neurostimulator helps regulate control, providing patients with effective and lasting relief.
Axonics began commercial activities for its SNM systems in Australia in March 2023. By May 2024, it received TGA approval to market its F15 recharge-free SNM system. Axonics also offers Bulkamid, a hydrogel used to treat female stress urinary incontinence in Australia.
Likely Trend of AXNX Stock Following the News
Following the news release, shares of AXNX declined 0.1% to $69.53 at yesterday's closing.
Shares of Axonics have gained 11.7% year to ...
